Trastuzumab Biosimilars Market 2020-2030: Global Industry Growth Factors, Trends, Demand Status and Forecast | Covid 19 Growth and Change

The Business Research Company offers "Trastuzumab Biosimilars Market Global Report 2020-30: Covid 19 Growth And Change" in its research report store. It is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by region and by country. It also compares the market’s historic and forecast growth, and highlights important trends and strategies that players in the market can adopt.

The global trastuzumab biosimilars market is expected to decline from $1.27 billion in 2019 to $1.25 billion in 2020 at a compound annual growth rate (CAGR) of -1.50%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $3.12 billion in 2023 at a CAGR of 35.50%.

Place a DIRECT PURCHASE ORDER of The Entire 140+ Pages Report @ https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3400

The trastuzumab biosimilar market consists of the sales of trastuzumab biosimilar and related services by entities (organizations, sole traders, and partnerships) that manufacture trastuzumab biosimilar. Trastuzumab is a monoclonal antibody that interferes with human epidermal growth factor receptor (HER2). Trastuzumab biosimilars are used mainly for the treatment of breast cancer and gastroesophageal junction adenocarcinoma or metastatic gastric.

The rising prevalence of breast and gastric cancer contributed to the growth of the trastuzumab biosimilar market. Trastuzumab biosimilar is used in the treatment of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer. According to the World Health Organization (WHO), in 2018, the new breast cancer cases registered were around 2.09 million, and stomach (gastric) cancer cases were around 1.03 million.

Trastuzumab Biosimilars Market Segmentation: -
By Product
Ogivri
Herzuma
Ontruzant
Trazimera
Others

By Indication
Adjuvant Breast Cancer
Metastatic Breast Cancer
Metastatic Gastric Cancer
Others

By Distribution Channel
Hospital Pharmacy
Online Pharmacy

Browse Complete Report @ https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilars-market-global-report-2020-30-covid-19-growth-and-change

Few Points From Table Of Content
1. Executive Summary
2. Trastuzumab Biosimilars Market Characteristics
3. Trastuzumab Biosimilars Market Size And Growth
4. Trastuzumab Biosimilars Market Segmentation
5. Trastuzumab Biosimilars Market Regional And Country Analysis
.
.
.
25. Trastuzumab Biosimilars Market Competitive Landscape And Company Profiles
26. Key Mergers And Acquisitions In The Trastuzumab Biosimilars Market
27. Trastuzumab Biosimilars Market Trends And Strategies
28. Trastuzumab Biosimilars Market Future Outlook and Potential Analysis
29. Appendix

The report covers the trends and market dynamics of the Trastuzumab Biosimilars Market in major countries - Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The report also includes consumer surveys and various future opportunities for the market.

Request for a Sample Copy of This Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=3400&type=smp

Some of the key players involved in the Trastuzumab Biosimilars Market are Amgen Inc., Pfizer Inc, Samsung Bioepis, Merck & Co., Biocon Limited, Mylan Inc., BioXpress Therapeutics, Celltrion.

Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on Blog: http://blog.tbrc.info/

About US:
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets after WHO declared COVID-19 as a pandemic.

This release was published on openPR.